These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

169 related articles for article (PubMed ID: 35393018)

  • 41. Stroke-Heart Syndrome: Incidence and Clinical Outcomes of Cardiac Complications Following Stroke.
    Buckley BJR; Harrison SL; Hill A; Underhill P; Lane DA; Lip GYH
    Stroke; 2022 May; 53(5):1759-1763. PubMed ID: 35354300
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Using machine learning to predict atrial fibrillation diagnosed after ischemic stroke.
    Zheng X; Wang F; Zhang J; Cui X; Jiang F; Chen N; Zhou J; Chen J; Lin S; Zou J
    Int J Cardiol; 2022 Jan; 347():21-27. PubMed ID: 34774886
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Significance of CHA
    Cheng X; Liu L; Li L; Zhao H; Li J; Shi J; Zhang W
    Intern Emerg Med; 2021 Aug; 16(5):1155-1163. PubMed ID: 33386603
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Midregional pro-atrial natriuretic peptide is a useful indicator for the detection of impaired left ventricular function in patients with coronary artery disease.
    Elmas E; Brueckmann M; Lang S; Kälsch T; Haghi D; Sueselbeck T; Dempfle CE; Borggrefe M
    Int J Cardiol; 2008 Aug; 128(2):244-9. PubMed ID: 17673312
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Midregional pro-atrial natriuretic peptide in the general population/Insights from the Gutenberg Health Study.
    Tzikas S; Keller T; Wild PS; Schulz A; Zwiener I; Zeller T; Schnabel RB; Sinning C; Lubos E; Kunde J; Münzel T; Lackner KJ; Blankenberg S
    Clin Chem Lab Med; 2013 May; 51(5):1125-33. PubMed ID: 23183754
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Midregional pro-A-type natriuretic peptide as part of a dual biomarker strategy for the early rule out of non-ST segment elevation acute coronary syndrome - The WilCop study.
    Tajsic M; Járai R; Koch J; Stangl K; Wojta J; Dreger H; Huber K
    Int J Cardiol; 2018 Dec; 273():243-248. PubMed ID: 30282602
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Comparison of midregional pro-atrial and B-type natriuretic peptides in chronic heart failure: influencing factors, detection of left ventricular systolic dysfunction, and prediction of death.
    Moertl D; Berger R; Struck J; Gleiss A; Hammer A; Morgenthaler NG; Bergmann A; Huelsmann M; Pacher R
    J Am Coll Cardiol; 2009 May; 53(19):1783-90. PubMed ID: 19422985
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Midregional Pro-Atrial Natriuretic Peptide and Atrial Fibrillation: Interesting Association or Practice Changing?
    Piccini JP; Harrington J
    J Am Coll Cardiol; 2022 Apr; 79(14):1382-1384. PubMed ID: 35393019
    [No Abstract]   [Full Text] [Related]  

  • 49. Score Using Measurements of Plasma Midregional Pro-Atrial Natriuretic Peptide to Estimate the Duration of Atrial Fibrillation.
    Legallois D; Sorbets E; Chenevier-Gobeaux C; Hallouche M; Boubaya M; Charnaux N; Lebon A; Levy V; Beygui F; Meune C
    J Appl Lab Med; 2017 Mar; 1(5):522-531. PubMed ID: 33379800
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Comparison of midregional pro-A-type natriuretic peptide and the N-terminal pro-B-type natriuretic peptide for predicting mortality and cardiovascular events.
    van Hateren KJ; Alkhalaf A; Kleefstra N; Groenier KH; de Jong PE; de Zeeuw D; Gans RO; Struck J; Bilo HJ; Gansevoort RT; Bakker SJ
    Clin Chem; 2012 Jan; 58(1):293-7. PubMed ID: 21948291
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Midregional pro-atrial natriuretic peptide: a novel marker of myocardial fibrosis in patients with hypertrophic cardiomyopathy.
    Elmas E; Doesch C; Fluechter S; Freundt M; Weiss C; Lang S; Kälsch T; Haghi D; Papassotiriou J; Kunde J; Schoenberg SO; Borggrefe M; Papavassiliu T
    Int J Cardiovasc Imaging; 2011 Apr; 27(4):547-56. PubMed ID: 20872251
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Predictors of newly diagnosed atrial fibrillation in cryptogenic stroke: a cohort study.
    Bugnicourt JM; Flament M; Guillaumont MP; Chillon JM; Leclercq C; Canaple S; Lamy C; Godefroy O
    Eur J Neurol; 2013 Oct; 20(10):1352-9. PubMed ID: 23121252
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Assessment of the CHA2DS2-VASc Score in Predicting Ischemic Stroke, Thromboembolism, and Death in Patients With Heart Failure With and Without Atrial Fibrillation.
    Melgaard L; Gorst-Rasmussen A; Lane DA; Rasmussen LH; Larsen TB; Lip GY
    JAMA; 2015 Sep; 314(10):1030-8. PubMed ID: 26318604
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Risk of New-Diagnosed Atrial Fibrillation After Transient Ischemic Attack.
    Purroy F; Vicente-Pascual M; Arque G; Begue R; Farre J; Gallego Y; Gil-Villar MP; Mauri G; Montalà N; Pereira C; Torres-Querol C; Vazquez-Justes D
    Front Neurol; 2022; 13():905304. PubMed ID: 35911925
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Prior ischemic strokes are non-inferior for predicting future ischemic strokes than CHA
    Bel-Ange A; Itskovich SZ; Avivi L; Stav K; Efrati S; Beberashvili I
    BMC Nephrol; 2021 May; 22(1):179. PubMed ID: 33992086
    [TBL] [Abstract][Full Text] [Related]  

  • 56. CHA2DS2-VASc score in acute ischemic stroke with atrial fibrillation: results from the Clinical Research Collaboration for Stroke in Korea.
    Lee HL; Kim JT; Lee JS; Kim BJ; Park JM; Kang K; Lee SJ; Kim JG; Cha JK; Kim DH; Park TH; Park SS; Lee KB; Lee J; Hong KS; Cho YJ; Park HK; Lee BC; Yu KH; Oh MS; Kim DE; Ryu WS; Choi JC; Kwon JH; Kim WJ; Shin DI; Sohn SI; Hong JH; Park MS; Choi KH; Cho KH; Lee J; Bae HJ
    Sci Rep; 2021 Jan; 11(1):793. PubMed ID: 33436977
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Validation of a Modified CHA2DS2-VASc Score for Stroke Risk Stratification in Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study.
    Chao TF; Lip GY; Liu CJ; Tuan TC; Chen SJ; Wang KL; Lin YJ; Chang SL; Lo LW; Hu YF; Chen TJ; Chiang CE; Chen SA
    Stroke; 2016 Oct; 47(10):2462-9. PubMed ID: 27625386
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Mid-regional proatrial natriuretic peptide for predicting prognosis in hypertrophic cardiomyopathy.
    Bégué C; Mörner S; Brito D; Hengstenberg C; Cleland JGF; Arbustini E; Galve E; Wichter T; Richter A; Golmard JL; Bernard M; Dubourg O; Komajda M; Charron P; Isnard R
    Heart; 2020 Feb; 106(3):196-202. PubMed ID: 31350276
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Increased plasma concentrations of midregional proatrial natriuretic Peptide is associated with risk of cardiorenal dysfunction in type 1 diabetes.
    Theilade S; Hansen TW; Goetze JP; Rossing P
    Am J Hypertens; 2015 Jun; 28(6):772-9. PubMed ID: 25468806
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Left atrial cross-sectional area is a novel measure of atrial shape associated with cardioembolic strokes.
    Tan TC; Nunes MCP; Handschumacher M; Pontes-Neto O; Park YH; O'Brien C; Piro V; Kim GM; Helenius J; Zeng X; Padilha da Silva JL; Furie K; Ay H; Hung J
    Heart; 2020 Aug; 106(15):1176-1182. PubMed ID: 31980438
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.